Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01498900
NCT01498900
Completed
Not Applicable

A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoNorm® in the Treatment of Type 2 Diabetic Patients in Routine Clinical Practice

Novo Nordisk A/S1 site in 1 country30,554 target enrollmentAugust 2004
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDiabetesDiabetes Mellitus, Type 2
Interventionsrepaglinide
Drugsrepaglinide

Overview

Phase
Not Applicable
Intervention
repaglinide
Conditions
Diabetes
Sponsor
Novo Nordisk A/S
Enrollment
30554
Locations
1
Primary Endpoint
HbA1c (glycosylated haemoglobin)
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSitesSimilar Trials

Overview

Brief Summary

This study is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy, safety and convenience of using repaglinide (NovoNorm®) in type 2 diabetes management in routine clinical practice.

Registry
clinicaltrials.gov
Start Date
August 2004
End Date
July 2006
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Type 2 diabetes
  • •Newly diagnosed or not adequately controlled with current therapy

Exclusion Criteria

  • Not provided

Arms & Interventions

Repaglinide

Intervention: repaglinide

Outcomes

Primary Outcomes

HbA1c (glycosylated haemoglobin)

Secondary Outcomes

  • Fasting Plasma Glucose (FPG)
  • Postprandial glucose values
  • Incidence of hypoglycaemia
  • Adverse drug reactions (ADR)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical PracticeDiabetesDiabetes Mellitus, Type 2
NCT01492166Novo Nordisk A/S1,935
Completed
Not Applicable
Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2Delivery Systems
NCT00715663Novo Nordisk A/S1,584
Completed
Not Applicable
Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2
NCT01536600Novo Nordisk A/S33,010
Completed
Not Applicable
Observational Study to Evaluate the Safety of Levemir® in DiabetesDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
NCT00659295Novo Nordisk A/S51,170
Completed
Not Applicable
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in JapanCongenital Bleeding DisorderGlanzmann's Disease
NCT01876745Novo Nordisk A/S4